Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lymphoma, Large B-Cell, Diffuse

ClinicalTrials.gov lists 1,827 trials for Lymphoma, Large B-Cell, Diffuse or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 123.

MeSH D016403 Neoplasms Neoplasm C04 C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 472 Phase 1/2 Phase 1/2 223 Phase 2 Phase 2 628 Phase 2/3 Phase 2/3 20 Phase 3 Phase 3 164 Phase 4 Phase 4 12 Not applicable Not applicable 111 Observational Observational 188 Phase 1 Phase 1 472 Phase 1/2 Phase 1/2 223 Phase 2 Phase 2 628 Phase 2/3 Phase 2/3 20 Phase 3 Phase 3 164 Phase 4 Phase 4 12 Not applicable Not applicable 111 Observational Observational 188

Trials per phase (log scale)

2 more sections with rows

1,817 of the 1,827 trials are tagged with Lymphoma, Large B-Cell, Diffuse itself; the rest are tagged with a narrower condition beneath it.

Get the Lymphoma, Large B-Cell, Diffuse report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lymphoma, Large B-Cell, Diffuse trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 96

1990: 4 trials (Not applicable 1, Phase 2 3) 1991: 2 trials (Phase 2 2) 1992: 6 trials (Observational 1, Phase 3 1, Phase 2 3, Phase 1 1) 1993: 5 trials (Observational 1, Phase 3 1, Phase 2 3) 1994: 5 trials (Phase 3 3, Phase 1 2) 1995: 9 trials (Phase 3 3, Phase 2 3, Phase 1/2 1, Phase 1 2) 1996: 14 trials (Observational 2, Not applicable 1, Phase 2 6, Phase 1 5) 1997: 36 trials (Observational 1, Not applicable 2, Phase 3 9, Phase 2/3 1, Phase 2 11, Phase 1/2 2, Phase 1 10) 1998: 36 trials (Not applicable 1, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 16, Phase 1/2 3, Phase 1 11) 1999: 54 trials (Observational 1, Not applicable 3, Phase 3 7, Phase 2/3 1, Phase 2 15, Phase 1/2 5, Phase 1 22) 2000: 53 trials (Observational 2, Not applicable 4, Phase 3 5, Phase 2 24, Phase 1/2 4, Phase 1 14) 2001: 28 trials (Not applicable 2, Phase 3 5, Phase 2 8, Phase 1/2 2, Phase 1 11) 2002: 40 trials (Observational 1, Not applicable 5, Phase 3 4, Phase 2 13, Phase 1/2 2, Phase 1 15) 2003: 44 trials (Observational 1, Not applicable 5, Phase 3 9, Phase 2/3 1, Phase 2 15, Phase 1/2 5, Phase 1 8) 2004: 50 trials (Observational 1, Not applicable 5, Phase 3 1, Phase 2 24, Phase 1/2 4, Phase 1 15) 2005: 53 trials (Observational 5, Not applicable 5, Phase 3 3, Phase 2 23, Phase 1/2 8, Phase 1 9) 2006: 55 trials (Observational 6, Not applicable 3, Phase 4 1, Phase 3 7, Phase 2 23, Phase 1/2 5, Phase 1 10) 2007: 65 trials (Other 1, Observational 5, Not applicable 7, Phase 3 6, Phase 2 29, Phase 1/2 2, Phase 1 15) 2008: 53 trials (Observational 10, Not applicable 1, Phase 3 4, Phase 2 15, Phase 1/2 9, Phase 1 14) 2009: 48 trials (Other 1, Observational 8, Not applicable 3, Phase 3 3, Phase 2 18, Phase 1/2 5, Phase 1 10) 2010: 49 trials (Observational 5, Not applicable 6, Phase 3 3, Phase 2/3 2, Phase 2 18, Phase 1/2 8, Phase 1 7) 2011: 51 trials (Observational 4, Not applicable 2, Phase 3 4, Phase 2 25, Phase 1/2 6, Phase 1 10) 2012: 39 trials (Observational 2, Not applicable 3, Phase 4 1, Phase 3 3, Phase 2 16, Phase 1/2 4, Phase 1 10) 2013: 53 trials (Observational 5, Not applicable 3, Phase 3 4, Phase 2/3 1, Phase 2 16, Phase 1/2 8, Phase 1 16) 2014: 36 trials (Observational 1, Phase 4 1, Phase 3 1, Phase 2 7, Phase 1/2 8, Phase 1 18) 2015: 57 trials (Observational 3, Not applicable 1, Phase 3 8, Phase 2 21, Phase 1/2 10, Phase 1 14) 2016: 79 trials (Observational 7, Not applicable 5, Phase 4 1, Phase 3 5, Phase 2/3 3, Phase 2 24, Phase 1/2 17, Phase 1 17) 2017: 72 trials (Observational 7, Not applicable 2, Phase 4 2, Phase 3 6, Phase 2/3 1, Phase 2 19, Phase 1/2 15, Phase 1 20) 2018: 63 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 5, Phase 2 19, Phase 1/2 6, Phase 1 26) 2019: 62 trials (Observational 6, Not applicable 3, Phase 3 6, Phase 2/3 1, Phase 2 17, Phase 1/2 6, Phase 1 23) 2020: 83 trials (Observational 17, Not applicable 3, Phase 3 8, Phase 2/3 1, Phase 2 21, Phase 1/2 16, Phase 1 17) 2021: 88 trials (Observational 16, Not applicable 3, Phase 4 1, Phase 3 13, Phase 2/3 1, Phase 2 22, Phase 1/2 11, Phase 1 21) 2022: 92 trials (Observational 16, Not applicable 6, Phase 4 1, Phase 3 6, Phase 2/3 2, Phase 2 29, Phase 1/2 12, Phase 1 20) 2023: 96 trials (Observational 18, Not applicable 9, Phase 4 1, Phase 3 3, Phase 2 27, Phase 1/2 11, Phase 1 27) 2024: 80 trials (Observational 11, Not applicable 9, Phase 3 5, Phase 2/3 1, Phase 2 30, Phase 1/2 6, Phase 1 18) 2025: 75 trials (Observational 13, Not applicable 1, Phase 3 4, Phase 2/3 2, Phase 2 32, Phase 1/2 11, Phase 1 12)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 67
2025 75
2024 80
2023 96
2022 92
2021 88
2020 83
2019 62
2018 63
2017 72

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 83 trials starting in 2026 and about 77 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 219 trials still running at the 2026-10-09 snapshot; registered median of 43 months across 1,144 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lymphoma, Large B-Cell, Diffuse trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 472
Phase 1/2 223
Phase 2 628
Phase 2/3 20
Phase 3 164
Phase 4 12
Not applicable 111
Observational 188
Expanded access 8
Unknown 1

How many Lymphoma, Large B-Cell, Diffuse trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 65
Recruiting 223
Enrolling by invitation 5
Active, not recruiting 120
Available 3

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lymphoma, Large B-Cell, Diffuse trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 123
Novartis Pharmaceuticals 26
Hoffmann-La Roche 24

Which drugs are being tested for Lymphoma, Large B-Cell, Diffuse? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
RITUXIMAB 364
Cytoxan 329
Prednisone 161
Melphalan 64

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Doxorubicine 157
Etoposid 156
Vincristina 155
SQ Fludarabine 127
Peripheral blood stem cell transplantation 114

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lymphoma, Large B-Cell, Diffuse trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 1,420 127
Pneumonia 724 121
Pyrexia 505 81
Neutropenia 492 69
Sepsis 395 104

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lymphoma, Large B-Cell, Diffuse? (739)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 Yes
International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma. Clinical lymphoma, myeloma & leukemia 2026 Yes
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study. Blood 2026 Yes
Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis. Blood advances 2026 Yes
Anti-CD19 antibody tafasitamab therapy for relapsed or refractory diffuse large B-cell lymphoma: a case series. Anti-cancer drugs 2026 Yes

Showing 5 of 739 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (78)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Diffuse large B-cell lymphoma Annual incidence 1-9 / 100 000 United Kingdom GB Exact
Diffuse large B-cell lymphoma Annual incidence 1-9 / 100 000 United Kingdom GB Exact
Diffuse large B-cell lymphoma Annual incidence 1-9 / 100 000 United Kingdom GB Unspecified
Diffuse large B-cell lymphoma Annual incidence 1-9 / 100 000 Lithuania Not stated Unspecified
Diffuse large B-cell lymphoma Annual incidence 1-9 / 1 000 000 Croatia Not stated Exact

Showing 5 of 78 prevalence observations.

Start your 14-day trial Email me the first 50 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Diffuse large B-cell lymphoma 544 Exact Orphanet Rare Disease Ontology (ORDO)
Diffuse large B-cell lymphoma 544 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages